Ignite Creation Date:
2024-05-05 @ 4:38 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00282828
Status:
COMPLETED
Last Update Posted:
2013-10-14
First Post:
2006-01-25
Brief Title:
Improving Treatment Outcomes in Pharmacotherapy of Generalized Social Anxiety Disorder
Sponsor:
Massachusetts General Hospital
Organization:
Massachusetts General Hospital
Study Overview
Official Title:
Improving Outcomes in Pharmacotherapy of Social Phobia
Status:
COMPLETED
Status Verified Date:
2013-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will compare the effectiveness of either adding clonazepam or placebo to standard treatment or switching to venlafaxine in treating generalized social anxiety disorder in individuals who have not responded to treatment with sertraline
Detailed Description:
Generalized social anxiety disorder GSAD is one of the most common psychiatric disorders and often causes significant distress and dysfunction in affected individuals Although currently available treatments for GSAD are effective most individuals have residual symptoms after initial psychosocial or psychopharmacologic intervention Further treatment is necessary for such individuals but sufficient research has not been done to guide clinicians on what the safest and most effective next step may be This study will compare the effectiveness of either combining clonazepam or placebo with sertraline or completely switching to venlafaxine in treating GSAD in individuals who have not responded to treatment with sertraline This study will also examine predictors of treatment response including factors such as age at disease onset duration of illness comorbidities and genes that influence serotonin and catecholamine metabolism
Participants in this double-blind study will first partake in an initial 10-week phase in which they will be treated with sertraline Participants who do not respond to sertraline treatment will proceed to phase two of the study in which they will be randomly assigned to one of three treatment groups One group will receive both sertraline and clonazepam another group will receive both sertraline and placebo and the third group will receive only venlafaxine All treatments will continue for 12 weeks Sertraline and venlafaxine are both FDA-approved for the treatment of GSAD Clonazepam is widely used for the treatment of anxiety but is not FDA-approved for the treatment of GSAD All participants will attend weekly study visits at Weeks 1 2 4 6 8 and 10 Participants who continue into phase two will attend weekly study visits at Weeks 11-14 16 18 20 and 22 Symptom remission rates and post-treatment social phobia severity will be assessed at Week 22
Participants in this double-blind study will first partake in an initial 10-week phase in which they will be treated with sertraline Participants who do not respond to sertraline treatment will proceed to phase two of the study in which they will be randomly assigned to one of three treatment groups One group will receive both sertraline and clonazepam another group will receive both sertraline and placebo and the third group will receive only venlafaxine All treatments will continue for 12 weeks Sertraline and venlafaxine are both FDA-approved for the treatment of GSAD Clonazepam is widely used for the treatment of anxiety but is not FDA-approved for the treatment of GSAD All participants will attend weekly study visits at Weeks 1 2 4 6 8 and 10 Participants who continue into phase two will attend weekly study visits at Weeks 11-14 16 18 20 and 22 Symptom remission rates and post-treatment social phobia severity will be assessed at Week 22
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| DSIR 83-ATAS | US NIH GrantContract | None | httpsreporternihgovquickSearchR01MH070919 |
| R01MH070919 | NIH | None | None |
| PA-01-123 | None | None | None |